Teleflex Expands Intraosseous Vascular Access Portfolio with New Arrow™ EZ-IO™ Intraosseous Access Procedure Tray
WAYNE, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a global leader in medical technologies and pioneer in intraosseous vascular access, today announced the launch of the Arrow™ EZ-IO™ Intraosseous Access Procedure Tray. This sterile, single-use tray includes all the components required for the IO access procedure, enabling a streamlined clinician workflow.
The new Arrow™ EZ-IO™ Procedure Tray includes the first FDA-cleared sterile, single-use, battery-powered driver, providing clinicians with an IO access option that can be used in a sterile field in the operation room and any other area of the hospital that requires a sterile field. The tray is packaged with an Arrow™ EZ-IO™ Intraosseous Needle Set (15mm, 25mm, or 45mm), which is designed to help ensure a fast,1 precise, and steady insertion. Additional components include:
- Pre-filled saline syringe and ChloraPrep™ Frepp™ Clear applicator
- EZ-Stabilizer™ Dressing
- EZ-Connect™ Extension Set
- SharpsAway™ II Locking Sharps Disposal Cup
- EZ-IO™ Patient Wristband
- Quick Reference Guide, printed on underside of every tray lidstock
"The Arrow™ EZ-IO™ Procedure Tray was developed after research was conducted with healthcare professionals who may benefit from an intraosseous access solution in a complete, convenient and sterile kit," stated Michelle Fox, Corporate Vice President and Chief Medical Officer at Teleflex. "This addition to our IO access portfolio reflects our relentless pursuit of innovation to empower clinicians and elevate patient care in challenging vascular access situations."
Delayed vascular access can result in treatment delays, which can lead to adverse outcomes.2-5 The Arrow™ EZ-IO™ Intraosseous Access System can be used when intravenous access is difficult or impossible to obtain in emergent, urgent, or medically necessary cases. In a recent survey of hospital-based clinicians, 65% recalled situations where their IO device was not accessible during a time-critical difficult vascular access situation.6 More than 75% of clinicians surveyed agree that a single-use tray would increase the accessibility and convenience of IO access devices.6 The new Arrow™ EZ-IO™ Procedure Tray was designed for compact storage on hospital shelving and is small enough to fit in any code cart.
Clinicians now have a choice between the reusable Arrow™ EZ-IO™ Power Driver and the new single-use tray. "The new Arrow™ EZ-IO™ Procedure Tray was designed to optimize efficiency in gaining fast vascular access while increasing the accessibility of the EZ-IO™ System," said Kevin Robinson, President and General Manager of Anesthesia and Emergency Medicine, Teleflex. "We listened to the challenges healthcare professionals face daily and are proud to introduce a solution that combines our industry-backed IO access device with enhanced convenience."
About Teleflex Incorporated
As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.
Teleflex is the home of Arrow™, Barrigel™, Deknatel™, QuikClot™, LMA™, Pilling™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.
At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties, and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.
Chloraprep and Frepp are trademarks of Carefusion or one of its subsidiaries.
Teleflex, the Teleflex logo, Arrow, EZ-IO, EZ-Connect, EZ-Stabilizer, Deknatel, LMA, Pilling, QuikClot, Rüsch, SharpsAway, UroLift and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries.© 2024 Teleflex Incorporated. All rights reserved. MC-009356
References:
- Davidoff J, Fowler R, Gordon D, et al. JEMS. 2005;30(10):s20-s23. Research sponsored by Teleflex Incorporated
- Donnino MW, Salciccioli JD, Howell MD, et al. BMJ. 2014;348:g3028.
- Gayet-Ageron A, Prieto-Merino D, Ker K, et al. Lancet. 2018;391(10116):125-132.
- Ferrer R, Martin-Loeches I, Phillips G, et al. Crit Care Med. 2014;42(8):1749-1755.
- Fonarow GC, Smith EE, Saver JL, et al. Circulation.2011;123(7):750-758
- Double-blinded online survey of n=209 respondents—including 159 target hospital-based clinicians in the Emergency Department, Trauma Unit, Intensive Care Unit/Critical Care Unit, or on the Rapid Response or Code Team—conducted 11-OCT-2022 to 21-OCT-2022. Teleflex data on file. D044709.
The Arrow™ EZ-IO™ Single-Use IO Tray is indicated for intraosseous access anytime in which vascular access is difficult to obtain in emergent, urgent or medically necessary cases for up to 24 hours. For patients ≥ 12 years old, the device may be extended for up to 48 hours when alternate intravenous access is not available or reliably established.
Rx Only.
CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician.
The Arrow™ EZ-IO™ Needle Set is Sterile, Single Use: Do not reuse, reprocess or re-sterilize. Reuse of device creates a potential risk of serious injury and/or infection which may lead to death. Refer to Instructions for Use for complete warnings, indications, contraindications, precautions, and potential complications.
Contact:
Teleflex Incorporated:
Lawrence Keusch
Vice President, Investor Relations and Strategy Development
investors.teleflex.com
610-948-2836
